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Background
Lyme borreliosis (LB) is multisystem infectious disease
with various clinical manifestations. In Europe, LB is
caused by gram-negative spirochetal bacteria of the
complex Borrelia burgdorferi sensu lato. The most
important for human pathogenicity are B. garinii,
B. afzelii and B.burgdorferi sensu stricto. Indirect labora-
tory diagnostics of LB is based on serological methods
such as Enzyme-Linked ImmunoSorbent Assay (ELISA)
and Western Blot Assay (WB) that detect specific antibo-
dies. Another method in the diagnostics of LB is a new
test LymeSpot. This test is based on Enzyme-Linked
ImmunoSpot Assay (ELISPOT). We present our first
experience with the test LymeSpot.
Methods
From November 2013 to June 2014 we performed
LymeSpot on the group of 42 patients who were tested
for suspicion of LB presence. LymeSpot is based on spe-
cific cell immune response of T-lymphocytes after sti-
mulation by Borrelia antigens. The result is a number of
antigen specific effector T-cells producing IFN-g in the
form of spots. We compared the results of LymeSpot
test with the level of specific IgM and IgG antibodies
detected by ELISA and WB with using recombinant
antigens B. burgdorferi sl.
Results
From the number of 42 patients we detected positive
LymeSpot test only in 4 of them (9,5%), a cutoff value in
3 patients (7,1%). From the group of 42 patients were
simultaneously performed ELISA and WB in 26 persons.
In this group we found positive LymeSpot in 4 patients
and cutoff value in 2 patients. In the group of 4 patients
with positive LymeSpot was detected higher level of IgM
antibodies in 3 patients and only IgG antibodies in 1
patient. They were patients with clinical manifestations
of LB who were treated with antibiotics afterwards.
Among 20 patients with negative results of LymeSpot
these findings correlated with antibody response in 8
patients (40%). In this group we detected seronegative
finding (IgM-IgG-) or finding of passing through LB
(IgM-IgG+). In other 12 patients with negative LymeSpot
test we detected serological finding of beginning (IgM
+IgG-) or running LB (IgM+IgG+). They were mostly
patients without clear symptoms of LB, patients with
long-term positivity of IgM antibodies without clinical
manifestations of LB or patients after antibiotic therapy.
Conclusions
Our first experience shows that results of LymeSpot test
better correlate with clinical findings and LB activity as
well as can be effective marker of success of antibiotic
therapy.
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